Coherus Oncology, Inc. (CHRS) Stock Analysis

Coherus Oncology’s principal competitive advantage is its ownership of LOQTORZI, a next-generation PD-1 inhibitor with FDA approval for nasopharyngeal carcinoma (NPC). LOQTORZI is the only preferred regimen in the NCCN guidelines for recurrent/metastatic NPC, supported by six-year survival data showing median overall survival of 64.8 months versus 33.7 months for chemotherapy alone—a 38% reduction in risk of death. This clinical differentiation has enabled LOQTORZI to double sales in 2025 to $40.8 million, despite a small U.S. NPC market (~2,000 cases/year).

The company’s strategy leverages LOQTORZI as both a revenue generator and a platform for pipeline combinations, notably with tagmokitug (CCR8 Treg depleter) and casdozokitug (IL-27 antagonist). This approach aims to create capital-efficient label expansions and potential entry into larger oncology markets.

Compared to rivals such as Merck (Keytruda), Bristol Myers Squibb (Opdivo), and BeiGene (tislelizumab), Coherus lacks scale and brand recognition but benefits from regulatory exclusivity: LOQTORZI enjoys 12 years of U.S. biologic exclusivity and orphan drug protection for NPC. However, the company’s competitive edge is fragile—its pipeline is shallow, and it pays a low-20% royalty on LOQTORZI sales to Junshi Biosciences, limiting margin expansion. Execution risk remains high, with future growth dependent on successful clinical readouts and disciplined capital allocation.